"The research has shown good preoperative auxiliary effect and safety." When Professor Si Lu from Beijing Cancer Hospital reported the clinical Iab data of recombinant human GM-CSF herpes simplex virus injection (OrienX010), Li Bingkun, founder of Aoyuan Heli, felt his worries lessen.

OrienX010 is a new gene therapy drug, which has been included in the priority review list of the Drug Evaluation Center of the State Food and Drug Administration. It is currently undergoing clinical trials for multiple indications.

Staff members conduct experiments

In 2017, Aoyuan Heli chose to enter the Beijing E-Town Biomedical Park, which greatly sped up passage of its new drugs from the laboratory to the clinic.

The Beijing Economic-Technological Development Area (BDA) has established a public service platform for biomedical technology to provide enterprises with service platforms such as early R&D and verification, pilot product amplification, production, and marketing. 

The cell therapy R&D pilot base under construction will become the country's largest professional carrier for the cell therapy industry. 

Beijing E-Town Biomedical Park Pilot Test Center

The park's factory site can be provided to different companies to meet the multiple needs of cell therapy products from R&D to pilot testing and production.

After Hehua Ruibo was registered in BDA, its knee joint surgical robot products completed compliance engineering research and development, passed registration inspection and entered the clinical stage within half a year.

Compared with similar cases, Hehua Ruibo had saved over one year’s time, thanks to the CRO platform for medical device engineering inspection and certification registration established by Beijing Zhongguancun Shuimu Medical Technology Co Ltd. 

Similarly, the clinical application of innovative drugs developed byEOC Pharma, Suzhou Yinhe and sciwind is attributed to Etinpro Co Ltd, a BDA enterprise.